Treatment Intensification in Locally Advanced/Unresectable NSCLC Through Combined Modality Treatment and Precision...

Area of Science:

• Oncology
• Radiation Oncology
• Medical Imaging

Background:

• The standard treatment for unresectable, locally advanced non-small cell lung cancer (NSCLC) involves concurrent chemoradiation followed by durvalumab.
• Despite this aggressive approach, a significant number of patients experience disease recurrence, either locally or distantly.

Purpose of the Study:

• To review ongoing therapeutic trials aimed at improving outcomes for patients with unresectable NSCLC.
• To highlight the role of quantitative imaging and precision radiation dose escalation in future treatment strategies.

Main Methods:

• Review of current clinical trials in unresectable NSCLC.
• Focus on treatment intensification strategies, including systemic agents and radiation dose adjustments.
• Emphasis on the integration of quantitative imaging for patient and tumor subset selection.

Main Results:

• Concurrent chemoradiation followed by durvalumab offers the best survival currently, but recurrence remains a challenge.
• Previous trials (e.g., RTOG 0617) indicated uniform dose escalation is not beneficial in unselected patients.
• Ongoing research focuses on selecting specific patient and tumor subsets that may benefit from escalated radiation doses.

Conclusions:

• Improving survival in unresectable NSCLC requires novel therapeutic approaches beyond the current standard of care.
• Precision radiation dose escalation, guided by quantitative imaging, holds promise for selected patients.
• Continued investigation into therapeutic trials is crucial for advancing treatment for unresectable NSCLC.